MHP
KPTI icon

Manatuck Hill Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Manatuck Hill Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,333
Closed -$458K – 116
2013
Q4 		$458K Buy
+1,333
New +$368K 0.06% 78

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manatuck Hill Partners's KPTI Position: Q1 2014 in Review

Manatuck Hill Partners sold out of Karyopharm Therapeutics (KPTI) in Q1 2014, closing a stake of 1,333 shares — an estimated $458K sold.

Manatuck Hill Partners first reported a position in KPTI in Q4 2013 and held it in 1 quarter. The position peaked at $458K in Q4 2013. 60 funds tracked by Wall St. Rank hold KPTI as of Q1 2014.

  • Manatuck Hill Partners reported no remaining Karyopharm Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Manatuck Hill Partners sold 1,333 Karyopharm Therapeutics shares in Q1 2014, an estimated $458K.
  • Manatuck Hill Partners first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 1 quarter.
  • Manatuck Hill Partners's Karyopharm Therapeutics position peaked at $458K in Q4 2013.
  • 60 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2014.

Based on Manatuck Hill Partners's 13F filing for Q1 2014, filed 15 May 2014.